<a href="https://www.fiercebiotech.com/medtech/roche-boosts-diagnostics-offering-595m-saga-buyout" hreflang="en">Roche boosts diagnostics offerings with $595M Saga buyout </a>
Roche is acquiring Saga Diagnostics for $595 million to enhance its Foundation Medicine business with Saga's advanced molecular residual disease platform, which improves cancer detection and monitoring. This deal aims to strengthen Roche's diagnostic offerings and expand patient access to high-quality tests globally.
Roche's acquisition of Saga Diagnostics for $595 million highlights a strategic move to enhance its Foundation Medicine business by integrating Saga's ultra-sensitive molecular residual disease (MRD) platform, Pathlight, which is already commercialized in early breast and colorectal cancer. This acquisition underscores the growing importance of precision diagnostics in supporting treatment selection, monitoring treatment response, and detecting disease recurrence, presenting a significant opportunity for stakeholders in precision medicine and diagnostics to explore partnerships or innovations that leverage similar ultra-sensitive detection technologies.